Medical - Diagnostics & Research
Compare Stocks
3 / 10Stock Comparison
DHR vs TMO vs A
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Diagnostics & Research
DHR vs TMO vs A — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $123.80B | $175.76B | $33.31B |
| Revenue (TTM) | $24.78B | $45.20B | $7.07B |
| Net Income (TTM) | $3.69B | $6.86B | $1.29B |
| Gross Margin | 60.7% | 39.4% | 38.8% |
| Operating Margin | 21.0% | 17.8% | 20.6% |
| Forward P/E | 20.7x | 19.0x | 19.7x |
| Total Debt | $18.42B | $40.85B | $3.35B |
| Cash & Equiv. | $4.62B | $9.86B | $1.79B |
DHR vs TMO vs A — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Danaher Corporation (DHR) | 100 | 118.4 | +18.4% |
| Thermo Fisher Scien… (TMO) | 100 | 135.4 | +35.4% |
| Agilent Technologie… (A) | 100 | 133.5 | +33.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DHR vs TMO vs A
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DHR is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.94, Low D/E 35.1%, current ratio 1.87x
- Beta 0.94 vs A's 1.23, lower leverage
TMO is the clearest fit if your priority is long-term compounding.
- 229.1% 10Y total return vs DHR's 218.0%
- Lower P/E (19.0x vs 20.7x), PEG 9.02 vs 34.20
- +16.6% vs DHR's -7.2%
A carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 10 yrs, beta 1.23, yield 0.8%
- Rev growth 6.7%, EPS growth 3.2%, 3Y rev CAGR 0.5%
- PEG 1.34 vs DHR's 34.20
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 6.7% revenue growth vs DHR's 2.9% | |
| Value | Lower P/E (19.0x vs 20.7x), PEG 9.02 vs 34.20 | |
| Quality / Margins | 18.3% margin vs DHR's 14.9% | |
| Stability / Safety | Beta 0.94 vs A's 1.23, lower leverage | |
| Dividends | 0.8% yield, 10-year raise streak, vs TMO's 0.4% | |
| Momentum (1Y) | +16.6% vs DHR's -7.2% | |
| Efficiency (ROA) | 10.1% ROA vs DHR's 4.5%, ROIC 13.5% vs 5.9% |
DHR vs TMO vs A — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
DHR vs TMO vs A — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DHR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 6.4x A's $7.1B. Profitability is closely matched — net margins range from 18.3% (A) to 14.9% (DHR). On growth, A holds the edge at +7.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $24.8B | $45.2B | $7.1B |
| EBITDAEarnings before interest/tax | $7.2B | $10.5B | $1.7B |
| Net IncomeAfter-tax profit | $3.7B | $6.9B | $1.3B |
| Free Cash FlowCash after capex | $5.3B | $6.7B | $993M |
| Gross MarginGross profit ÷ Revenue | +60.7% | +39.4% | +38.8% |
| Operating MarginEBIT ÷ Revenue | +21.0% | +17.8% | +20.6% |
| Net MarginNet income ÷ Revenue | +14.9% | +15.2% | +18.3% |
| FCF MarginFCF ÷ Revenue | +21.4% | +14.9% | +14.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.7% | +6.2% | +7.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +9.8% | +11.3% | -3.6% |
Valuation Metrics
DHR leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 25.8x trailing earnings, A trades at a 26% valuation discount to DHR's 34.7x P/E. Adjusting for growth (PEG ratio), A offers better value at 1.75x vs DHR's 34.20x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $123.8B | $175.8B | $33.3B |
| Enterprise ValueMkt cap + debt − cash | $137.6B | $206.8B | $34.9B |
| Trailing P/EPrice ÷ TTM EPS | 34.71x | 26.66x | 25.75x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.73x | 19.04x | 19.71x |
| PEG RatioP/E ÷ EPS growth rate | 34.20x | 12.62x | 1.75x |
| EV / EBITDAEnterprise value multiple | 18.14x | 18.99x | 19.74x |
| Price / SalesMarket cap ÷ Revenue | 5.04x | 3.94x | 4.79x |
| Price / BookPrice ÷ Book value/share | 2.37x | 3.33x | 4.96x |
| Price / FCFMarket cap ÷ FCF | 23.54x | 27.93x | 28.92x |
Profitability & Efficiency
A leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
A delivers a 18.7% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $7 for DHR. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), DHR scores 7/9 vs A's 5/9, reflecting strong financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | +7.1% | +13.2% | +18.7% |
| ROA (TTM)Return on assets | +4.5% | +6.4% | +10.1% |
| ROICReturn on invested capital | +5.9% | +7.5% | +13.5% |
| ROCEReturn on capital employed | +7.0% | +9.1% | +14.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.35x | 0.76x | 0.50x |
| Net DebtTotal debt minus cash | $13.8B | $31.0B | $1.6B |
| Cash & Equiv.Liquid assets | $4.6B | $9.9B | $1.8B |
| Total DebtShort + long-term debt | $18.4B | $40.9B | $3.4B |
| Interest CoverageEBIT ÷ Interest expense | 18.13x | 5.89x | 19.53x |
Total Returns (Dividends Reinvested)
Evenly matched — TMO and A each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMO five years ago would be worth $10,211 today (with dividends reinvested), compared to $7,907 for DHR. Over the past 12 months, TMO leads with a +16.6% total return vs DHR's -7.2%. The 3-year compound annual growth rate (CAGR) favors A at -3.1% vs DHR's -5.6% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | -23.9% | -20.1% | -14.3% |
| 1-Year ReturnPast 12 months | -7.2% | +16.6% | +12.8% |
| 3-Year ReturnCumulative with dividends | -15.9% | -11.9% | -9.0% |
| 5-Year ReturnCumulative with dividends | -20.9% | +2.1% | -7.7% |
| 10-Year ReturnCumulative with dividends | +218.0% | +229.1% | +202.6% |
| CAGR (3Y)Annualised 3-year return | -5.6% | -4.2% | -3.1% |
Risk & Volatility
Evenly matched — DHR and TMO each lead in 1 of 2 comparable metrics.
Risk & Volatility
DHR is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than A's 1.23 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.94x | 1.10x | 1.23x |
| 52-Week HighHighest price in past year | $242.80 | $643.99 | $160.27 |
| 52-Week LowLowest price in past year | $172.06 | $385.46 | $104.36 |
| % of 52W HighCurrent price vs 52-week peak | +72.0% | +73.4% | +73.4% |
| RSI (14)Momentum oscillator 0–100 | 32.3 | 39.8 | 52.2 |
| Avg Volume (50D)Average daily shares traded | 4.1M | 1.9M | 2.0M |
Analyst Outlook
A leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: DHR as "Buy", TMO as "Buy", A as "Buy". Consensus price targets imply 41.2% upside for DHR (target: $247) vs 38.4% for TMO (target: $655). For income investors, A offers the higher dividend yield at 0.84% vs TMO's 0.36%.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $247.00 | $654.67 | $166.00 |
| # AnalystsCovering analysts | 42 | 42 | 38 |
| Dividend YieldAnnual dividend ÷ price | +0.7% | +0.4% | +0.8% |
| Dividend StreakConsecutive years of raises | 1 | 8 | 10 |
| Dividend / ShareAnnual DPS | $1.23 | $1.69 | $0.99 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.5% | +1.7% | +1.3% |
DHR leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). A leads in 2 (Profitability & Efficiency, Analyst Outlook). 2 tied.
DHR vs TMO vs A: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DHR or TMO or A a better buy right now?
For growth investors, Agilent Technologies, Inc.
(A) is the stronger pick with 6. 7% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). Agilent Technologies, Inc. (A) offers the better valuation at 25. 8x trailing P/E (19. 7x forward), making it the more compelling value choice. Analysts rate Danaher Corporation (DHR) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DHR or TMO or A?
On trailing P/E, Agilent Technologies, Inc.
(A) is the cheapest at 25. 8x versus Danaher Corporation at 34. 7x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Agilent Technologies, Inc. wins at 1. 34x versus Danaher Corporation's 34. 20x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — DHR or TMO or A?
Over the past 5 years, Thermo Fisher Scientific Inc.
(TMO) delivered a total return of +2. 1%, compared to -20. 9% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: TMO returned +229. 1% versus A's +202. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DHR or TMO or A?
By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.
94β versus Agilent Technologies, Inc. 's 1. 23β — meaning A is approximately 31% more volatile than DHR relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — DHR or TMO or A?
By revenue growth (latest reported year), Agilent Technologies, Inc.
(A) is pulling ahead at 6. 7% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, A leads at 0. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DHR or TMO or A?
Agilent Technologies, Inc.
(A) is the more profitable company, earning 18. 8% net margin versus 14. 7% for Danaher Corporation — meaning it keeps 18. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: A leads at 21. 3% versus 18. 2% for TMO. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DHR or TMO or A more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Agilent Technologies, Inc. (A) is the more undervalued stock at a PEG of 1. 34x versus Danaher Corporation's 34. 20x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 0x forward P/E versus 20. 7x for Danaher Corporation — 1. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 41. 2% to $247. 00.
08Which pays a better dividend — DHR or TMO or A?
All stocks in this comparison pay dividends.
Agilent Technologies, Inc. (A) offers the highest yield at 0. 8%, versus 0. 4% for Thermo Fisher Scientific Inc. (TMO).
09Is DHR or TMO or A better for a retirement portfolio?
For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
94), 0. 7% yield, +218. 0% 10Y return). Both have compounded well over 10 years (DHR: +218. 0%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DHR and TMO and A?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
DHR, A pay a dividend while TMO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.